JP4491072B2 - ビトロネクチンレセプター拮抗物質 - Google Patents

ビトロネクチンレセプター拮抗物質 Download PDF

Info

Publication number
JP4491072B2
JP4491072B2 JP51694298A JP51694298A JP4491072B2 JP 4491072 B2 JP4491072 B2 JP 4491072B2 JP 51694298 A JP51694298 A JP 51694298A JP 51694298 A JP51694298 A JP 51694298A JP 4491072 B2 JP4491072 B2 JP 4491072B2
Authority
JP
Japan
Prior art keywords
oxo
benzazepine
tetrahydro
propyloxy
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP51694298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001501936A5 (enExample
JP2001501936A (ja
Inventor
キャラハン，ジェイムズ・フランシス
カズンズ，ラッセル・ドノバン
キーナン，リチャード・マッカロック
クウォン，チェット
ミラー，ウィリアム・ヘンリー
ユジンカス，アイリーン・ナイジョル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of JP2001501936A publication Critical patent/JP2001501936A/ja
Publication of JP2001501936A5 publication Critical patent/JP2001501936A5/ja
Application granted granted Critical
Publication of JP4491072B2 publication Critical patent/JP4491072B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP51694298A 1996-10-02 1997-10-01 ビトロネクチンレセプター拮抗物質 Expired - Fee Related JP4491072B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2732096P 1996-10-02 1996-10-02
US60/027,320 1996-10-02
US4377697P 1997-04-11 1997-04-11
US60/043,776 1997-04-11
PCT/US1997/018001 WO1998014192A1 (en) 1996-10-02 1997-10-01 Vitronectin receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009235447A Division JP2010006838A (ja) 1996-10-02 2009-10-09 ビトロネクチンレセプター拮抗物質

Publications (3)

Publication Number Publication Date
JP2001501936A JP2001501936A (ja) 2001-02-13
JP2001501936A5 JP2001501936A5 (enExample) 2005-05-12
JP4491072B2 true JP4491072B2 (ja) 2010-06-30

Family

ID=26702318

Family Applications (2)

Application Number Title Priority Date Filing Date
JP51694298A Expired - Fee Related JP4491072B2 (ja) 1996-10-02 1997-10-01 ビトロネクチンレセプター拮抗物質
JP2009235447A Pending JP2010006838A (ja) 1996-10-02 2009-10-09 ビトロネクチンレセプター拮抗物質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009235447A Pending JP2010006838A (ja) 1996-10-02 2009-10-09 ビトロネクチンレセプター拮抗物質

Country Status (36)

Country Link
EP (1) EP0957917B1 (enExample)
JP (2) JP4491072B2 (enExample)
KR (1) KR100589578B1 (enExample)
CN (1) CN1114403C (enExample)
AP (1) AP1463A (enExample)
AR (1) AR008878A1 (enExample)
AT (1) ATE312089T1 (enExample)
AU (1) AU733417B2 (enExample)
BG (1) BG64581B1 (enExample)
BR (1) BR9712248B1 (enExample)
CA (1) CA2267224C (enExample)
CO (1) CO4900046A1 (enExample)
CY (1) CY2576B1 (enExample)
CZ (1) CZ299076B6 (enExample)
DE (1) DE69734833T2 (enExample)
DK (1) DK0957917T3 (enExample)
DZ (1) DZ2320A1 (enExample)
EA (1) EA002419B1 (enExample)
ES (1) ES2252775T3 (enExample)
HU (1) HU229221B1 (enExample)
ID (1) ID19623A (enExample)
IL (1) IL129243A (enExample)
MA (1) MA24361A1 (enExample)
MY (1) MY137606A (enExample)
NO (1) NO320194B1 (enExample)
NZ (1) NZ334953A (enExample)
PE (1) PE10499A1 (enExample)
PL (1) PL190859B1 (enExample)
RO (1) RO119881B1 (enExample)
SA (1) SA98180936B1 (enExample)
SK (1) SK285029B6 (enExample)
TR (1) TR199900737T2 (enExample)
TW (1) TW487702B (enExample)
UA (1) UA60311C2 (enExample)
UY (2) UY24735A1 (enExample)
WO (1) WO1998014192A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010006838A (ja) * 1996-10-02 2010-01-14 Smithkline Beecham Corp ビトロネクチンレセプター拮抗物質

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
IL135189A0 (en) * 1997-09-24 2001-05-20 Smithkline Beecham Corp Vitronectin receptor antagonist
JP2002500162A (ja) * 1997-09-24 2002-01-08 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
WO2000038715A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
EP1150965A4 (en) * 1999-02-03 2002-05-15 Merck & Co Inc BENZAZEPINE DERIVATIVES AS ALPHA-V INTGRIN RECEPTOR ANTAGONISTS
MXPA01011052A (es) * 1999-04-30 2002-11-22 Univ Michigan Aplicaciones terapeuticas de benzodiazepinas pro-apoctoticas.
JP2003506452A (ja) * 1999-08-06 2003-02-18 スミスクライン・ビーチャム・コーポレイション 発作の治療に有用なビトロネクチン受容体アンタゴニスト
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10027514A1 (de) * 2000-06-06 2002-01-03 Basf Ag Liganden von Integrinrezeptoren
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002060438A1 (en) 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
CN1248692C (zh) * 2001-04-10 2006-04-05 史密丝克莱恩比彻姆公司 玻璃体结合蛋白受体拮抗剂在制备用于抑制粘连形成的药物中的用途
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
EP1387688A2 (en) * 2001-05-03 2004-02-11 Merck & Co., Inc. Benzazepinone alpha v integrin receptor antagonists
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
WO2004089890A2 (en) * 2003-04-04 2004-10-21 Smithkline Beecham Corporation Process and intermediates for preparing benzazepines
EP1734996B1 (en) * 2004-04-02 2013-05-22 The Regents of The University of California Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
TW200635902A (en) * 2004-12-21 2006-10-16 Smithkline Beecham Corp Methods and formulations
EP1968594B1 (en) * 2005-11-29 2010-09-29 GlaxoSmithKline LLC Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
EP2221308B1 (en) * 2007-11-16 2013-07-10 Ube Industries, Ltd. Benzazepinone compound
US8076475B2 (en) * 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
EP2415474B1 (en) * 2009-03-30 2013-08-28 Ube Industries, Ltd. Pharmaceutical composition for treatment or prevention of ophthalmic diseases
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
JP5755647B2 (ja) 2009-07-24 2015-07-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア αｖβ５インテグリンに関連する疾患の処置および予防のための方法および組成物
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
EP2325194A1 (en) * 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
BR112022021228A2 (pt) * 2020-04-26 2022-12-06 Jiangsu Nhwa Pharmaceutical Co Ltd Derivado da 1,5-di-hidro-2,4-benzodiazepin-3-ona e aplicação do mesmo
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236882T1 (de) * 1992-12-21 2003-04-15 Smithkline Beecham Corp Bicyklische fibrinogen antagoniste
ZA955391B (en) * 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
WO1996000730A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
JPH10504825A (ja) * 1994-08-22 1998-05-12 スミスクライン・ビーチャム・コーポレイション 二環式化合物
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010006838A (ja) * 1996-10-02 2010-01-14 Smithkline Beecham Corp ビトロネクチンレセプター拮抗物質

Also Published As

Publication number Publication date
UY24735A1 (es) 1998-03-30
JP2010006838A (ja) 2010-01-14
CA2267224A1 (en) 1998-04-09
NO320194B1 (no) 2005-11-14
SK42599A3 (en) 1999-12-10
UA60311C2 (uk) 2003-10-15
CY2576B1 (en) 2008-07-02
SA98180936B1 (ar) 2006-05-30
EA002419B1 (ru) 2002-04-25
AU733417B2 (en) 2001-05-17
PL332674A1 (en) 1999-09-27
AU4746297A (en) 1998-04-24
DK0957917T3 (da) 2006-04-18
CN1238689A (zh) 1999-12-15
EA199900356A1 (ru) 2000-02-28
DZ2320A1 (fr) 2002-12-28
EP0957917A4 (en) 2002-05-15
ES2252775T3 (es) 2006-05-16
AP9901493A0 (en) 1999-03-31
CN1114403C (zh) 2003-07-16
TR199900737T2 (xx) 1999-07-21
AP1463A (en) 2005-09-10
CO4900046A1 (es) 2000-03-27
ATE312089T1 (de) 2005-12-15
HU229221B1 (en) 2013-09-30
CZ113299A3 (cs) 2000-03-15
BR9712248A (pt) 1999-08-24
EP0957917B1 (en) 2005-12-07
ID19623A (id) 1998-07-23
MA24361A1 (fr) 1998-07-01
WO1998014192A1 (en) 1998-04-09
IL129243A (en) 2004-07-25
CZ299076B6 (cs) 2008-04-16
KR100589578B1 (ko) 2006-06-15
DE69734833T2 (de) 2006-07-13
AR008878A1 (es) 2000-02-23
JP2001501936A (ja) 2001-02-13
NO991590L (no) 1999-05-31
NO991590D0 (no) 1999-03-31
CA2267224C (en) 2007-03-13
PL190859B1 (pl) 2006-02-28
MY137606A (en) 2009-02-27
BR9712248B1 (pt) 2010-06-29
BG64581B1 (bg) 2005-08-31
HK1023730A1 (en) 2000-09-22
PE10499A1 (es) 1999-03-27
RO119881B1 (ro) 2005-05-30
UY24935A1 (es) 2001-07-31
BG103299A (en) 2000-01-31
IL129243A0 (en) 2000-02-17
DE69734833D1 (de) 2006-01-12
SK285029B6 (sk) 2006-04-06
HUP9903769A2 (hu) 2000-03-28
KR20000048816A (ko) 2000-07-25
TW487702B (en) 2002-05-21
HUP9903769A3 (en) 2000-07-28
EP0957917A1 (en) 1999-11-24
NZ334953A (en) 2000-01-28

Similar Documents

Publication Publication Date Title
KR100589578B1 (ko) 비트로넥틴 수용기 길항제
US6239138B1 (en) Vitronectin receptor antagonist
JP2002528380A (ja) ビトロネクチン受容体アンタゴニスト
JP2002500162A (ja) ビトロネクチン受容体アンタゴニスト
US6825188B2 (en) Vitronectin receptor antagonists
US6458814B1 (en) Vitronectin receptor antagonists
US20020019387A1 (en) Vitronectin receptor antagonist
US20020128257A1 (en) Vitronectin receptor antagonist
HK1023730B (en) Vitronectin receptor antagonists
MXPA00002895A (en) Vitronectin receptor antagonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080909

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081010

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091009

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100330

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100405

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130409

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140409

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees